Potential New Treatment Identified for Liver Disease: Study miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.
The approval makes odevixibat the second IBAT inhibitor approved for the rare genetic disease, with capability to benefit both liver damage and itch symptoms.
The 2030 goal for global elimination of HCV looks out of reach so as key patient population including those who inject drugs are out of clinician's reach, one expert explains.
The genetic rare disease is characterized by a greater risk of premature mortality and worsened quality of life. Emerging IBAT inhibitors are helping address both issues.
Intercept Pharma (ICPT) Reports Efficacy and Safety Data from Phase 3 REGENERATE Study streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.